SELLAS Advances Blood Cancer Treatment with “Tremendous Therapeutic Promise”MCAP MediaWire • 10/11/23
SELLAS Announces First Patient Dosed in Phase Ib/II Trial of SLS009 (GFH009) in Relapsed/Refractory Peripheral T-cell LymphomasGlobeNewsWire • 10/11/23
SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Acute Myeloid LeukemiaGlobeNewsWire • 10/10/23
SELLAS SLS009 Phase 1 Clinical Study Successfully Achieves All Primary and Secondary EndpointsMCAP MediaWire • 09/22/23
SELLAS Announces Positive Topline Data in Lymphoma Cohort from SLS009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints MetGlobeNewsWire • 09/21/23
SELLAS Life Sciences to Participate in the Cantor Fitzgerald Global Healthcare ConferenceGlobeNewsWire • 09/18/23
SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue Without any ModificationsGlobeNewsWire • 08/22/23
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2023 Financial ResultsGlobeNewsWire • 08/10/23
SELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural MesotheliomaGlobeNewsWire • 06/28/23
SELLAS Announces First Patient Dosed in Phase 2a Clinical Trial of GFH009 in Acute Myeloid LeukemiaGlobeNewsWire • 06/22/23
SELLAS Life Sciences Announces Abstract Accepted for Presentation at International Gynecologic Cancer Society Annual MeetingGlobeNewsWire • 06/15/23
SELLAS Life Sciences to Present Phase 3 REGAL Trial in Progress Poster at 2023 ASCO Annual MeetingGlobeNewsWire • 05/25/23
SELLAS Life Sciences to Host Virtual Expert Panel Discussion on GFH009 in Acute Myeloid LeukemiaGlobeNewsWire • 05/16/23
SELLAS Life Sciences Provides Business Update and Reports First Quarter 2023 Financial ResultsGlobeNewsWire • 05/11/23
SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual MeetingGlobeNewsWire • 04/26/23
SELLAS Life Sciences Successfully Completes Phase I Trial Dose Escalation of Novel, Highly Selective CDK9 Inhibitor GFH009 in Acute Myeloid LeukemiaGlobeNewsWire • 04/20/23
SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as PlannedGlobeNewsWire • 04/18/23
Top 5 Health Care Stocks That Preparing To Pump This Quarter - Enovis (NYSE:ENOV), Esperion Therapeutics (NASDAQ:ESPR)Benzinga • 03/29/23
SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 03/16/23
SELLAS Announces Publication of Positive GPS Clinical Data in Ovarian Cancer in Peer Reviewed JournalGlobeNewsWire • 03/07/23
Sellas Life Sciences raises $20 million from public offering of stock, warrantsMarket Watch • 02/24/23
SELLAS Life Sciences Announces Pricing of $20.0 Million Underwritten Public OfferingGlobeNewsWire • 02/24/23